Dual signal amplification by polysaccharide and eATRP for ultrasensitive detection of CYFRA 21–1 DNA

Publication date: Available online 15 November 2019Source: Biosensors and BioelectronicsAuthor(s): Liying Zhao, Huaixia Yang, Xiaoke Zheng, Jinge Li, Lihe Jian, Weisheng Feng, Jinming KongAbstractCytokeratin fragment antigen 21–1 (CYFRA 21–1) DNA is a crucial biomarker closely associated with non-small cell lung cancer. Here, we fabricated a novel electrochemical biosensor for ultrasensitive detection of CYFRA 21–1 DNA via polysaccharide and electrochemically mediated atom transfer radical polymerization (eATRP) dual signal amplification. Specifically, thiolated peptide nucleic acid (PNA) probes at 5′-terminals are immobilized on the gold electrode surface for specific recognition of CYFRA 21–1 DNA (tDNA). After hybridization, hyaluronic acid (HA) is linked to the hybridized PNA/DNA duplexes via the recognized carboxylate-Zr4+-phosphate chemistry. Then multiple initiators of the polymerization reaction are introduced via esterification reaction. Lastly, large numbers of electro-active monomers are successfully grafted from the initiation sites of functionalized HA by eATRP reaction, significantly amplifying the electrochemical signal. Under optimal conditions, the constructed sensor can detect as low as 9.04 aM tDNA. Further, this proposed biosensor can also be applied to the direct detection of double-stranded DNA (dsDNA), obtaining 0.12 fM as the detection limit. Besides, this strategy shows high selectivity for mismatched bases and excellent...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research

Related Links:

ConclusionsThese two urinary proteins could serve as potential markers for the diagnosis of NSCLC.
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
MONDAY, Dec. 9, 2019 -- For newly diagnosed patients with non-small cell lung cancer (NSCLC), depressive symptoms are common and often accompanied by other symptoms, according to a study published online Nov. 21 in Lung Cancer. Barbara L. Andersen,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
AbstractAs part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (AstraZeneca) of durvalumab (IMFINZITM) to submit evidence for the clinical and cost effectiveness of durvalumab for the treatment of patients with locally advanced, unresectable, stage III non-small cell lung cancer whose tumours express programmed death-ligand 1 (PD-L1) on  ≥ 1% of tumour cells and whose disease has not progressed after platinum-based chemoradiation therapy. Kleijnen Systematic Reviews Ltd, in collaboration with Maastricht University Medi...
Source: PharmacoEconomics - Category: Health Management Source Type: research
ConclusionsOur results indicate that compared with crizotinib and alectinib, ceritinib is a cost-effective option for treatment-na ïve patients with ALK-positive advanced NSCLC.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
This study investigated the effect of miR-133a on cell proliferation in non-small cell lung cancer (NSCLC). The expression of miR-133a and YES proto-oncogene 1 (YES1) was detected using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay. The CCK-8 assay was used to measure cell proliferation. The relationship between miR-133a and YES1 was confirmed by dual luciferase assay. Downregulation of miR-133a was identified in NSCLC and correlated with poor prognosis in NSCLC patients. Moreover, the overexpression of miR-133a inhibited proliferation of NSCLC cells. YES1 was also confirmed as a direct targe...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Nobili S, Lavacchi D, Perrone G, Vicini G, Tassi R, Landini I, Grosso A, Roviello G, Mazzanti R, Santomaggio C, Mini E Abstract The use of vinorelbine as single agent or in combination regimens in NSCLC is associated with satisfactory clinical activity. However, the role of vinorelbine-based chemotherapy in chemonaive locally advanced unresectable or metastatic NSCLC patients, according to real-world treatment patterns, has still not widely explored. Eighty-one patient treated at a single institution were retrospectively analyzed. Thirty-seven received standard first-line single-agent vinorelbine, 44 vinor...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
Authors: Jankowska-Polańska B, Polański J, Chabowski M, Rosińczuk J, Mazur G Abstract The purpose of this study was to evaluate the influence of cognitive adjustment to cancer, assessed on the mini-Mental Adjustment to Cancer (mini-MAC) scale, on perception of anxiety and depression, assessed with the Hospital Anxiety and Depression Scale, in patients with non-small cell lung carcinoma (NSCLC). There were 185 patients, grouped according to the score of mini-MAC into constructive coping strategies, balanced coping strategies, and destructive coping strategies. We found that patients with predominantly destructive...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Publication date: Available online 4 December 2019Source: Life SciencesAuthor(s): Jie-Qiong Liu, Yu-Hua Feng, Shan Zeng, Mei-Zuo ZhongAbstractAimsNon-small cell lung cancer (NSCLC), characterized by extensive metastasis and poor prognosis, is the most common type of lung cancer. Dysregulation of certain lncRNAs is known to be linked to the tumorigenesis of NSCLC. However, the specific roles in NSCLC for many other lncRNAs, such as linc01088, remain largely unknown.Materials and methodsThe expression patterns of linc01088, p21 and EZH2 were examined both in NSCLC tissues and cell lines using RT-qPCR assay. CCK-8, colony for...
Source: Life Sciences - Category: Biology Source Type: research
Authors: Blakely CM, Riess JW Abstract Introduction: Lung cancer is the leading cause of cancer-related deaths, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancer cases. The continued advancement of DNA sequencing technology and the discovery of multiple specific driver mutations underlying many cases of NSCLC are moving clinical intervention toward a more targeted approach. Here we focus on anaplastic lymphoma kinase (ALK), a member of the receptor tyrosine kinase family, as an oncogenic driver in NSCLC. The ALK gene is rearranged in 3-7% of NSCLCs, and targeted inhibition ...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Non–small cell lung cancer (NSCLC), since the recognition of epidermal growth factor receptor (EGFR) mutations that sensitized tumors to EGFR tyrosine kinase inhibitors, has been a poster child for precision oncology in solid tumors. The emergence of resistance to the EGFR tyrosine kinase inhibitors led to the unveiling of multiple resistance mechanisms that are now recognized to be frequent mechanisms across multiple tumor types. Coevolution of technological advancements in testing methods available to clinical laboratories now has identified a growing number of molecularly defined subsets of NSCLC that have new the...
Source: Advances in Anatomic Pathology - Category: Pathology Tags: Review Articles Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Chemistry | Environmental Health | Lung Cancer | Non-Small Cell Lung Cancer